Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden · Delayed Price · Currency is SEK 301.60
+6.40 (2.17%)
Oct 15, 2025, 5:00 PM CET
STO:SOBI Revenue
Swedish Orphan Biovitrum AB had revenue of 6.18B SEK in the quarter ending June 30, 2025, with 13.47% growth. This brings the company's revenue in the last twelve months to 26.97B, up 13.75% year-over-year. In the year 2024, Swedish Orphan Biovitrum AB had annual revenue of 26.03B with 17.65% growth.
Revenue (ttm)
26.97B
Revenue Growth
+13.75%
P/S Ratio
3.86
Revenue / Employee
13.92M
Employees
1,806
Market Cap
104.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
| Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
| Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
| Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
| Dec 31, 2020 | 15.26B | 1.01B | 7.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sectra AB | 3.37B |
| Getinge AB | 35.50B |
| Camurus AB | 2.27B |
| Medicover AB | 25.22B |
| Asker Healthcare Group AB | 15.88B |
| BioArctic AB | 1.86B |
| AddLife AB | 10.44B |
| Vitrolife AB | 3.54B |
Swedish Orphan Biovitrum AB News
- 26 days ago - KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - Seeking Alpha
- 26 days ago - Ionis Pharmaceuticals And Sobi Say EU Approves TRYNGOLZA For Familial Chylomicronemia Syndrome - Nasdaq
- 4 weeks ago - Swedish Orphan Biovitrum AB (Publ) (SWOBY) Discusses On NASP And Uncontrolled Gout Call (Transcript) - Seeking Alpha
- 4 weeks ago - Swedish Orphan Biovitrum AB (publ) - Special Call - Seeking Alpha
- 5 weeks ago - 10 stocks to consider if you want alternatives to the expensive S&P 500 - Market Watch
- 3 months ago - Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Swedish Orphan Biovitrum AB (publ) 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Swedish Orphan Biovitrum AB (BIOVF) Reports Strong Q2 Revenue Growth - GuruFocus